The Myelin Repair Foundation's president has issued a statement about its collaboration with the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health (NIH), about advancing new generic drug compound now being called MRF-008.
This compound—which we will refer to as MRF-008—is a generic drug our academic research consortium has identified as a potential candidate to protect and repair myelin in MS patients. Since MRF-008 is already FDA-approved for another disease indication, the MRF and the NIH see a tremendous opportunity to investigate the repurposing of this drug to protect and repair myelin in multiple sclerosis patients.
The statement (January 2014) can be seen in its entirety
here.